Enumeral Biomedical Holdings Inc
Enumeral Biomedical — Technical Presentation (November 2015)
23 slides from Enumeral Biomedical's technical presentation, Nov 18, 2015
Slide 1: PD-1 Program Update: Differentiated Anti-PD-1 Antibody Functional Characterization in Ex Vivo Human Lung Biopsy Assays
EnumeralPD-1 Program Update: Differentiated Anti-PD-1 Antibody Functional Characterization in Ex VivoHuman Lung Biopsy Assays November 18, 2015
Slide 2: Background
Background • Enumeraluses a unique single cell technology platform and approach to identify functionally differentiated antibody candidates – Enumeralhas identified two classes of anti-PD-1 antibodies with distinct modes of binding to PD-1 – Both classes demonstrate enhancement of T cell activation
Slide 3: Enumeral's Approach to Developing Differentiated Antibodies Starts with Diversity
Enumeral’sApproach to Developing Differentiated Antibodies Starts with Diversity • Enumeralantibody discovery results in exceptional diversity* • Potential for strong IP position • Breadth of diversity: keys to unlocking the target physiology • Multiple potential program opportunities OPDIVO® KEYTRU
Slide 4: Enumeral PD-1 Program
EnumeralPD-1 Program • Enumeralhas identified a novel potentially allosteric anti-PD-1 antagonist (ENUM 244C8) displaying the following properties: – Reversal of PD-L1-dependent immunosuppression – Binding to PD-1 via a novel epitope – Increased levels of T cell activation in cell-based assays – Bin
Slide 5: Methods
Ex Vivo Reversal of TIL Exhaustion: Methods • NSCLC samples from staging surgeries were analyzed within 24 hours of collection • Flow cytometry analyzed extent of T cell infiltration and co- expression of immunomodulatory receptors (PD-1 and TIM-3) • Cells were incubated with anti-CD3/anti-CD28 anti
Slide 6: Example Flow Cytometry Analysis
Ex Vivo Reversal of TIL Exhaustion: Example Flow Cytometry Analysis 6 NSCLC WD36444 contains 14% T cells
Slide 7: Co-expression of Immunomodulatory Receptors (IMRs)
Ex Vivo Reversal of TIL Exhaustion: Co- expression of Immunomodulatory Receptors (IMRs) • WD36444 CD4+ and CD8+ TILs express exhaustion markers (IMRs) • PD-1 expressed on 55% of CD4 cells and 75% of CD8 cells • ‘IMR X’ expressed 5.5% of CD4 cells and 13% of CD8 cells 7 CD4 cells CD8 cells P D - 1 Im
Slide 8: Variability Across Patients
Ex Vivo Reversal of TIL Exhaustion: Variability Across Patients 8 Tumor Identifier % EpCAM-CD45+ %CD3+ %CD4 + PD-1 + %CD8 + PD-1 + %CD4 + TIM3 + %CD8 + TIM3 + WD-36444* 25.7 14 55 75 5.5 13 WD-36571* 10.3 6.3 47 64 1.8 <1 WD-36686* 21.6 17 55 84 6 16 WD-36790* 16.8 10.4 38 68 1 5.2 WD-36904* 12.8 7
Slide 9: Experimental Questions
Ex Vivo Reversal of TIL Exhaustion: Experimental Questions • Tumor biopsy from n=10 patients found to harbor TILs that express exhaustion markers including PD-1. 1. What is the activity of the T cells following activation? – If cells do not produce IFN-in response to TCR triggering (anti-CD3 + anti
Slide 10: PD-1 blockade can restore function to T cells derived from human lung biopsy
Ex Vivo Reversal of TIL Exhaustion: PD-1 blockade can restore function to T cells derived from human lung biopsy Functional modification of TILs with PD-1 blockade using NSCLC tumor WD36444 containing 25.7% lymphocytes. The indicated antibodies used at 20 ug/mL.ENUMC8-1, ENUMC8-2, and ENUMC8-3 are h
Slide 11: PD-1 blockade can restore function to T cells derived from human lung biopsy
Ex Vivo Reversal of TIL Exhaustion: PD-1 blockade can restore function to T cells derived from human lung biopsy 11 NSCLC WD36571 Functional modification of Tumor infiltrating lymphocytes with PD-1 blockade. 3e5 WD36571 tumor cells containing 10 % lymphocytes were activated in the presence of anti-C
Slide 12: PD-1 blockade can restore function to T cells derived from human lung biopsy
Ex Vivo Reversal of TIL Exhaustion: PD-1 blockade can restore function to T cells derived from human lung biopsy 12 NSCLC WD36988 ENUM 244C8 elicits increased interferon- secretioncompared to ENUM 388D4 Functional modification of Tumor infiltrating lymphocytes with PD-1 blockade. 3e5 WD36988 tumor
Slide 13: Responsiveness of TILs to PD-1 blockade varies among patients
Ex Vivo Reversal of TIL Exhaustion: responsiveness of TILs to PD-1 blockade varies among patients 13 NSCLC WD36904 Despite presence of active TIL infiltrate anti-PD-1 antibodies did not elicit enhanced T cell function Functional modification of NSCLC Tumor infiltrating lymphocytes with PD-1 blockade
Slide 14: Responsiveness of TILs to PD-1 blockade varies among patients
Ex Vivo Reversal of TIL Exhaustion: responsiveness of TILs to PD-1 blockade varies among patients 14 NSCLC M115801A2 Functional modification of Tumor infiltrating lymphocytes with PD-1 blockade. 3e5 M115801A2 tumor cells containing 3.4 % lymphocytes were activated in the presence of anti-CD3+anti-CD
Slide 15: Additive effects of two anti-PD-1 antibodies
15 Functional modification of Tumor infiltrating lymphocytes with PD-1 blockade. 3e5 WD36790 tumor cells containing 16.8 % lymphocytes were tested with the indicated antibodiesat the listed concentrations. NSCLC WD36790 Ex Vivo Reversal of TIL Exhaustion: additive effects of two anti-PD-1 antibodies
Slide 16: Additive effects of two anti-PD-1 antibodies
Ex Vivo Reversal of TIL Exhaustion: additive effects of two anti-PD-1 antibodies 16 Functional modification of NSCLC Tumor infiltrating lymphocytes with PD-1 blockade. 3e5 WD36686 tumor cells containing 21.6% lymphocytes were activated in the presence of anti-CD3+anti-CD28 and the indicated antibodi
Slide 17: Summary of Experimental Observations
Ex Vivo Reversal of TIL Exhaustion: Summary of Experimental Observations • Tumor biopsy from n=10 patients were found to harbor TILs that express exhaustion markers including PD-1. • IFN-production was measured as an indicator of reversal of T cell exhaustion following incubation with anti-CD3/anti
Slide 18: Responsiveness Correlated with TIL Infiltrates
Ex Vivo Reversal of TIL Exhaustion: Responsiveness Correlated with TIL Infiltrates • Each experiment was evaluated and the TILs were determined to be responsive or non-responsive to anti-PD-1 antibodies – Responsiveness was scored based on whether statistically significant elevation in IFN-producti
Slide 19: Responsiveness Correlated with Increased CD4 expression
Ex Vivo Reversal of TIL Exhaustion: Responsiveness Correlated with Increased CD4 expression 19 N o n r e s p o n d e r R e s p o n d e r 0 2 4 6 8 CD8 % P value 0.2960 Ex Vivo Reversal of TIL Exhaustion: hypo- responsiv
Slide 20: Hyporesponsiveness associated with increased CD4+PD-1+ and CD4+TIM-3+ levels
eness associated with increased CD4 + PD-1 + and CD4 + TIM-3 + levels 20 N o n r e s p o n d e r R e s p o n d e r 0 20 40 60 80 100 %CD4+ PD-1+ % P value 0.0445 N o n r e s p o n d e r R e s p o n d e r -10 0 10 20 30 %CD4+ TIM-3+ % P value 0.0569 N o n r e s p o n d e r R e s p o n d e r 0 20 40 6
Slide 21: Summary of NSCLC findings to date
Summary of NSCLC findings to date • NSCLC tumors contain varying levels of TILs that are heterogeneous in expression levels of lineage markers (CD4, CD8) and immunomodulatory receptors (PD-1, TIM-3) • Experimental Summary: 50% of samples analyzed found to harbor TILs responsive to PD-1 blockade ex v
Slide 22: Conclusions
Conclusions • ENUM 244C8 is a pharmacologically distinct humanized anti-PD- 1 antibody that binds PD-1 non-competitively with PD-L1 • Incubation with anti-CD3/anti-CD28 antibodies results in limited reversal of exhaustion of NSCLC tumor-derived T cells; PD-1 blockade is required to enhance IFN-secr
Slide 23: The Power of Human
THE POWER ofHUMAN™
Enumeral Biomedical Holdings — Technical Presentation (November 2015) on 6ix